Biovica's rights issue fully subscribed, HDF to take up unsold shares

what happened

Biovica International AB reported via TradingView that its rights issue of B-shares, offered with preferential rights to existing holders, has been fully subscribed. The subscription window closed on 21 October 2026. Roughly 49.97% of the offered shares were taken up using subscription rights, and about 21.14% were requested without them.

The remaining roughly 28.89% will go to HDF Cancer Monitoring BV as guarantor, though part of that allocation depends on Sweden's Inspectorate of Strategic Products. Shares lifting HDF above about 29.9% of votes will be allocated only after the regulator approves the investment or closes the notification. If cleared, the company expects proceeds of about SEK 29.2 million before issue costs. The share count will rise from 291,911,199 to 389,214,932.

why it matters

Shareholders who did not take part will see their stake diluted by 25.00% of shares and 23.27% of votes, and HDF's guarantee commission adds roughly 1.78% more dilution. Trading in the new shares is expected in early November, which will noticeably increase the number of tradable shares. For the company, the main gain is the capital raised; for existing holders, the cost is a smaller ownership share.

tags

instruments